3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
42
Breast
15
Genitourinary
14
CNS
13
Dermatologic
12
Other hematologic neoplasm
11
Lymphoid
11
Plasma cell
10
Myeloid
10
Sarcoma
6
Gastrointestinal
4
Thoracic
2
Other solid neoplasm
2
Head & Neck
2
Endocrine
2
Other
1
NET
1
Classical hematology
1
Conditions
Neuroendocrine Tumors
394
Carcinoid Tumor
49
Gastro-enteropancreatic neuroendocrine tumor
42
Neoplasms
36
Carcinoma, Neuroendocrine
36
Adenoma, Islet Cell
27
Neoplasm Metastasis
23
Pancreatic Neoplasms
22
Colorectal Neoplasms
21
Pheochromocytoma
20
Paraganglioma
19
Sarcoma
15
Gastrointestinal Neoplasms
15
Carcinoma
14
Breast Neoplasms
14
Stomach Neoplasms
13
Prostatic Neoplasms
13
Neuroblastoma
13
Lung Neoplasms
13
Carcinoma, Hepatocellular
13
Thyroid Neoplasms
12
Small Cell Lung Carcinoma
12
Carcinoma, Renal Cell
11
Cholangiocarcinoma
10
Neuroectodermal Tumors, Primitive
9
Carcinoma, Non-Small-Cell Lung
9
Somatostatinoma
8
Serotonin Syndrome
8
Digestive System Neoplasms
8
Brain Neoplasms
8
Interventions
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gestational Trophoblastic Disease
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled